Supplementary material

Preservative and Safety Testing: Methods

Preservative efficacy and safety testing was performed and is described in supplementary material. Preservative efficacy was assessed in an independent contract laboratory (Silliker Australia, Regents Park, Australia) to ensure the products met the requirements listed in the United States Pharmacopeia Chapter 51 for the Efficacy of Antimicrobial Preservation test of Category - 2 Products (http://www.usp.org/). Repeat insult patch testing was performed by AMA laboratories (New City NY, USA) using a cohort of 50 individuals. Healthy adult individuals, free from dermatologic disorders were inducted with informed consent in accordance with US Code of Federal Regulations Title 21, Part 50. Participants were excluded from the study if they were using medications, topical or systemic, that could potentially interfere with the test results. Pregnant and lactating females were also excluded. Test patches (Parke-Davis Hypoallergenic Readi Bandages) were prepared with 0.2 mL of the test material and applied to the infrascapular regions of the back. The patch was then removed after 24 hours. The procedure was repeated until 9 consecutive 24 hour exposures had been made for every Monday, Wednesday and Friday for 3 consecutive weeks. On the presentation of any adverse reactions, the area of erythema or edema was measured relative to unaffected normal skin, 24 hours post patch removal. After 10-14 days of rest following the initial 9 exposures, the participants were challenged with the test material again, applied at a previously unexposed site. Reactions were scored as above at 24 and 48 hours post application.

Preservative and Safety Testing: Results

Formulations met the preservative efficacy requirements. We tested our évolis® product base with no active compounds and évolis® with 0.095% or 0.5% MTP3 for safety. A 50 participant repeated insult patch test for the test products was performed and monitored for adverse reactions. All three products were extremely well tolerated with zero adverse reactions recorded (Supplementary Table ST1). indicating that they were non-primary irritants and non-primary sensitizers according to FDA designation.[1]

Dermal Papilla Cell PCR

Dermal Papilla cells were grown as described in the methods section for the DP-ALP assay and were treated with 0.3 μg/mL FGF5 and 10nM Wnt3a (R&D Systems, USA), 10nM Wnt3a alone, or were left untreated. RNA was extracted from cells using the RNeasy mini kit (Qiagen, Germany). cDNA was prepared using the ReverTra Ace-α- kit (Toyobo, Japan). Quantitative real-time PCR was performed using appropriate forward and reverse primers and the SYBR Premix Ex TaqII (Tli RNaseH Plus, Takara Bio Inc, Japan) on a Thermal Cycler Dice® (TP-850, Takara Bio Inc, Japan). Data generated from each PCR reaction were analyzed using Thermal Cycler Dice® Real Time System Single Software ver4.02 (Takara Bio Inc, Japan). Transcript levels were normalized to β-Actin.

Scientifically matched photography

We performed quantitative analysis of hair volume using high resolution scientifically matched photography, carried out in a controlled environment in an independent laboratory (AMA Laboratories, New City NY, USA). Photographs were converted to a format which allowed quantitation of hair density using PhotoGrammetrix®. The procedure reduced full color pictures to a two color image, with the scalp showing black and hair showing green. Pixel density was then quantified and was reflective of hair density. The results of the analysis of 3 male and 3 female participants from the 0.095% MTP3 group are shown in Supplementary Fig. 5. All participants had an increase in the density of hair at day 56, and 5 out of 6 participants continued to show an increase in hair density up to day 112. Due to large differences in baseline, we analyzed the increase in hair density as a function of baseline (Fig.8 main text). Both groups had improvements over baseline at both time points as described above, and we observed a significant increase in hair density with respect to baseline at day 112 compared to day 56 ($p = 0.03$, Fig 8 in main body), further highlighting the continued improvement in hair density for this group of participants applying the topical formulation with 0.095% MTP3.

1. US FDA. Appraisal of the Safety of Chemicals in Food, Drugs and Cosmetics. 1965.

Supplementary Figure 1

A



B



Effect of adding FGF5 to Wnt activated DP cells in culture. FGF5 added to Wnt activated DP cells reduces ALP activity (A) ($p = 0.0003$). ALP is an indicator of anagen, and a reduction of ALP is an indicator of catagen induction. Addition of FGF5 to these cells also reduces ALP transcription (B), indicating that the presence of FGF5 is having a regulatory effect. ALP mRNA levels are increased when DP cells are incubated with Wnt3a ($p = 0.0002$), subsequent treatment of Wnt3a activated cells with FGF5 results in reduced mRNA levels of ALP ($p = 0.004$)

Supplementary Figure 2



We separated the data into male (BLACK) and female (RED), and performed statistical analysis on the combined treated groups. For the AT ratio, there was a significant difference from baseline in both male ($p = 0.007$) and female ($p = 0.003$) (A), with the effect most apparent at day 112 ($p = 0.02$ and $p = 0.016$ for female and male respectively). No differences were evident in the placebo group (B). Separation into the different treatment arms also identified significant differences in female and male 0.5%MTP3 arms ($p = 0.046$ and $p = 0.049$ respectively), and trends in the female and male 0.095%MTP3 arms ($p = 0.075$ and $p = 0.054$ respectively). Effect comparisons with respect to baseline between groups (treated vs placebo) (C) suffered from low sample numbers and high variance in both the male and the female placebo group, but in the male subgroup we saw a borderline significant difference compare to placebo ($p = 0.08$), that was not seen in the whole cohort analysis. All females improved in AT ratio compared to baseline.

Supplementary Figure 3



We separated the data into male (BLACK) and female (RED), and performed statistical analysis on the combined treated groups (i.e. 0.095 plus 0.5% MTP3). For hair fall, a significant difference from baseline in both male ($p = 0.002$) and female ($p = 0.012$) groups was evident (A), with the effect seen at both time points but most apparent at day 112 for females ($p = 0.02$) and day 56 for males ($p = 0.001$). No differences were seen in the female placebo group, and in the male placebo group there was a significant increase in hair fall at day 112 ($p = 0.02$) (B). Separation into the different treatment arms also identified significant differences in male 0.095 %MTP3 arm ($p = 0.0076$), and trends in the female and male 0.5%MTP3 arms ($p = 0.1$ and $p = 0.075$ respectively), and in the female 0.095% MTP3 arm ($p = 0.074$). Effect comparisons with respect to baseline between groups (treated vs placebo) (C) suffered from low sample numbers which resulted in poor statistical power, but in the male subgroup we saw a significant difference in both treatment arms compared to placebo: 0.095% $p = 0.001$ and

0.5% p = 0.006). All treated females improved in hair fall compared to baseline and to a larger magnitude on average than placebo.

Supplementary Figure 4



We separated the data into male (BLACK) and female (RED), and performed statistical analysis on the combined treated groups. For visual grading, there was a significant difference from baseline in both male (p = 0.002) and female groups (p = 0.038), with the effect most apparent at day 112 for females (p = 0.026) and males (p = 0.005) (A). No differences were seen in the placebo groups (B). Separation into the different treatment arms also identified significant differences in female 0.5 %MTP3 arm (p = 0.01), and the male 0.095% MTP3 arm (p = 0.000005), and a borderline result for the male 0.5% MTP3 arm (p = 0.14). Effect comparisons with respect to baseline between groups (treated vs placebo)(C) suffered from low sample numbers which resulted in poor statistical power, but in the male subgroup

we saw significant differences in compared to placebo ($p = 0.03$) All but one treated female improved in grading compared to baseline group in which only one of three placebo females did, and we saw a trend for improvement in females compared to placebo ($p = 0.075$).

Supplementary Figure 5



Supplementary Figure 5. Scientifically matched photography of participants from the 0.095% MTP3 treatment arm. There was an increase in pixels (PX) from baseline to day 112, and a continued increase

day 0 - day 56 - day 112 for 5 out of 6 participants (illustrated in row 4). One participant, male 1, had a very slight decrease day 56-112 after a large increase between days 0-56. Those images with boxes indicate the area from which the pixel counts were taken. Images without those gates indicate entire image was used for assessment. All Males were Hamilton-Norwood scale 3. Females 2 and 3 were Ludwig scale I-3, Female 1 was Ludwig scale I-2

	Safety: Repeated insult patch testing results
Response	**Explanation**
0	No evidence of any effect
?	Barely perceptible, minimal faint, light pink, uniform or spotty erythema
1	Mild pink uniform erythema covering most of contact site
2	Moderate pink/red erythema visibly uniform in entire contact area
3	Marked bright red erythema with accompanying edema, petechiae or papules
4	Severe deep red erythema with vesiculation or weeping with or without edema
D	Patch eliminated due to reaction
Dc	Discontinued due to absence of subject on application date
M	Patch applied on adjacent site after strong test reaction
N/A	Score not calculated for subjects discontinued before challenge
S	Skin stained from pigment in product
T	Tan

			Response									Challenge		Score
Participant	**Race**	**Sex**	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**24 Hr**	**48 Hr**	
Placebo_1	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_2	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_3	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_4	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_5	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_6	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_7	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_8	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_9	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_10	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_11	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_12	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_13	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_14	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_15	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_16	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_17	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_18	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_19	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_20	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_21	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_22	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_23	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_24	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_25	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_26	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_27	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_28	Asian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_29	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_30	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_31	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0

			Response									Challenge		Score
Participant	**Race**	**Sex**	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**24 Hr**	**48 Hr**	
Placebo_32	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_33	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_34	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_35	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_36	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_37	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_38	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_39	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_40	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_41	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_42	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_43	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_44	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_45	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_46	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_47	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_48	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_49	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
Placebo_50	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0

			Response									Challenge		Score
Participant	Race	Sex	1	2	3	4	5	6	7	8	9	24 Hr	48 Hr	
0.095% MTP3_1	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_2	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_3	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_4	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_5	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_6	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_7	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_8	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_9	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_10	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_11	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_12	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_13	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_14	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_15	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_16	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_17	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_18	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_19	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_20	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_21	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_22	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_23	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_24	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_25	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_26	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_27	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_28	Asian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_29	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_30	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_31	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0

			Response									Challenge		Score
Participant	**Race**	**Sex**	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**24 Hr**	**48 Hr**	
0.095% MTP3_32	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_33	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_34	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_35	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_36	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_37	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_38	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_39	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_40	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_41	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_42	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_43	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_44	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_45	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_46	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_47	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_48	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_49	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.095% MTP3_50	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0

			Response									Challenge		Score
Participant	**Race**	**Sex**	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**24 Hr**	**48 Hr**	
0.5% MTP3_1	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_2	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_3	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_4	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_5	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_6	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_7	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_8	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_9	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_10	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_11	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_12	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_13	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_14	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_15	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_16	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_17	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_18	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_19	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_20	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_21	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_22	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_23	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_24	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_25	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_26	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_27	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_28	Asian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_29	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_30	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_31	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0

			Response									Challenge		Score
Participant	**Race**	**Sex**	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**24 Hr**	**48 Hr**	
0.5% MTP3_32	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_33	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_34	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_35	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_36	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_37	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_38	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_39	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_40	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_41	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_42	Caucasian	Male	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_43	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_44	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_45	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_46	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_47	Hispanic	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_48	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_49	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0
0.5% MTP3_50	Caucasian	Female	0	0	0	0	0	0	0	0	0	0	0	0